CLINICAL EVALUATION OF DKB ON INFECTIOUS DISEASES OF CHILDREN

• Published in: CHEMOTHERAPY Vol. 22; no. 5; pp. 861 - 864
• Main Authors: NUNOUE, TADASU, HIRANO, YOSHITO, NAGAYAMA, TOKURO, MIYAHARA, TOSHIHIKO
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1974
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.22.861

The DKB was used for the treatment of children with the bacterial infections or a probable mycoplasma infection. The 14 cases include the 3 cases of simple urinary tract infection, the 14 cases include the 3 cases of simple urinary tract infection, the 4 cases of the complicated urinary tract infection, the 3 of sepsis or suspected sepsis, the 3 of the respiratory tract infection and a case of primary atypical pneumonia. The DKB was given intramuscularly once or twice divided a day, at the dosage for 1.0mg/kg/day and 2.3 mg/kg/day, which seemed to be effective for the non-complicated infection. The Pseudomonas infection was as well treated with DKB as the E. coli and the staphylococcal infection, but PAP was not. No abnormal response was recognized locally. The elevation of serum transaminase value and BUN after the use was detected in two cases and one respectively, and the appearance of the granular casts in the urine was found during the administration in a case. No other abnormal findings were revealed on the urinalysis and the kidney and liver function test. Those abnormal findings in the laboratory data should be confirmed to be or not really the side-effect of DKB furthermore.